RPO NucleoGenesis

Gent ·KBO/BCE: BE 0782.980.238

Loading dossier…

Metric	This company	Sector median	Position in the sector
Solvency	19.0%	28.3%	better than 40% of 38 sector peers
Net result	€3k	€-22k	better than 59% of 38 sector peers
Equity	€20k	€71k	better than 36% of 39 sector peers
Gross operating margin	€8k	€45k	better than 45% of 31 sector peers
Total assets	€108k	€432k	better than 22% of 38 sector peers

Line item	Code	2023
Balance sheet, Assets
TOTAL ASSETS	20/58	€108k
Current assets	29/58	€108k
Amounts receivable within one year	40/41	€11k
Cash & bank	54/58	€97k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€108k
Equity	10/15	€20k
Contributions / capital	10/11	€18k
Accumulated profits (losses)	14	€3k
Amounts payable	17/49	€87k
Amounts payable within one year	42/48	€87k
Trade debts payable within one year	44	€73k
Income statement
Gross operating margin	9900	€8k
Operating result	9901	€5k
Financial income	75	€42
Financial charges	65	€1k
Result before taxes	9903	€4k
Income taxes	67/77	€802
Net result for the period	9904	€3k
Result to be appropriated	9905	€3k

NACE primary	Vervaardiging van farmaceutische grondstoffen(21100)
Legal form	Private limited company(610)
Incorporation	08-03-2022
Status	Active
Postal code	9031

Summary